Solving the complexity of MSI analysis from genomic data
Improving MSI Diagnosis with Next-Generation Sequencing
MSIcare is a cutting-edge software as a medical device. It aims to improve the detection of MSI biomarker in solid cancer using next-generation sequencing (NGS) technology.
We demonstrate the current limitations of NGS-based data interpretation algorithms. Thanks to our extensive expertise, we improve the computational detection of MSI based on our own specific analytical parameters.
By leveraging the power of NGS data, MSIcare can provide highly accurate and reliable MSI diagnosis. Clinicians are enabling to make more informed treatment decisions and improve patient outcomes.
MSIcare also offers powerful features for research purposes or clinical research applications.
Explore MSIcare to unlock the potential of precision medicine
Scalable to pan-cancer analysis
Compatible with Whole-Exome or Targeted-Genome Sequencing data
Tumor tissue analysis without referencing with normal specimen
Compatible with genomic data from tissue or blood samples
Run from FASTQ or BAM files
Optimized panel of microsatellite markers based on the tumor type
Empower your labs to deliver high-performance MSI testing
Use advanced genomic analysis algorithms to enable MSI research in any type of solid cancer and at any stage of the disease
Interpret raw genomic data in routine clinic
Provide a comprehensive assessment of the genetic profile of tumors, for more precise and personalized treatment strategies